Goyal, L., Ellis, H., Borad, M., Kim, R. D., Ahnert, J. R., Starodub, A., Valle, J. W., Bridgewater, J., Russell, J., Ali, A., Moynihan, K., Little, M., Zou, L., Lawrence, J., Vogel, A. (2025). A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3171